Allotransplantation for chronic lymphocytic leukemia.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic stem cell transplantation (alloSCT) is a focus for curative treatment strategies in chronic lymphocytic leukemia (CLL).
• The primary anti-leukemic mechanism of alloSCT in CLL is attributed to graft-versus-leukemia (GVL) effects, mediated by the donor immune system.
• GVL can induce durable suppression of the CLL clone, as evidenced by minimal residual disease kinetics post-transplantation.

Purpose of the Study:

• To evaluate the efficacy of alloSCT in overcoming treatment resistance in poor-risk CLL.
• To assess the role of GVL in achieving complete and durable suppression of the leukemic clone.
• To determine the appropriate patient selection criteria and timing for alloSCT in CLL.

Main Methods:

• Analysis of minimal residual disease kinetics following alloSCT.
• Evaluation of GVL effects in patients with CLL.
• Review of outcomes in patients with poor-risk CLL undergoing alloSCT, including those with purine analogue refractory disease and del 17p-.

Main Results:

• AlloSCT can overcome treatment resistance in poor-risk CLL, including purine analogue refractory disease and CLL with del 17p-.
• GVL effects contribute to complete and durable suppression of the leukemic clone.
• AlloSCT, even with reduced-intensity conditioning, carries significant risks of mortality and morbidity from graft-versus-host disease.

Conclusions:

• AlloSCT is a viable treatment option for select patients with poor-risk CLL who meet specific criteria.
• The timing of alloSCT is critical; it should be performed before the disease becomes completely refractory to optimize outcomes.
• Ongoing prospective trials aim to confirm whether alloSCT can alter the natural history of poor-risk CLL.